Stock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing

Stock Track

Dec 23, 2024

Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.

The European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.

Blarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137770145"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137770145\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137770145?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137770145","market":"us","top_or_hot":-1,"title":"Stock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing","media":"Stock Track","content":"<p>Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.</p>\n\n<p>The European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.</p>\n\n<p>Blarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Anavex Life Sciences Soars 9.85% in Pre-Market on EMA Acceptance of Alzheimer's Drug Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-12-23 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.</p>\n\n<p>The European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.</p>\n\n<p>Blarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVXL","symbol_name":"Anavex Life Sciences Corp.","start_time":0,"source_url":"","article_id":"1137770145","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137770145","pubTimestamp":1734956668,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Anavex Life Sciences Corp.  witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.The European Medicines Agency  has accepted for review Anavex's Marketing Authorization Application  for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVXL":"Anavex Life Sciences Corp."},"translate_title":"EMA接受阿尔茨海默氏症药物申请后，Anavex Life Sciences盘前股价飙升9.85%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":1},"content_text":"Anavex Life Sciences Corp. (AVXL) witnessed a significant surge of 9.85% in its stock price during the pre-market trading session on Monday. This rally was fueled by positive news regarding the company's Alzheimer's disease drug candidate, blarcamesine.\nThe European Medicines Agency (EMA) has accepted for review Anavex's Marketing Authorization Application (MAA) for blarcamesine, an investigational oral treatment for Alzheimer's disease. This development brings the company a step closer to potentially offering a novel treatment option for Alzheimer's patients in Europe.\nBlarcamesine has demonstrated promising results in clinical trials, including the ability to slow cognitive decline in early-stage Alzheimer's patients while exhibiting a favorable safety profile. The drug aims to target the underlying pathology of Alzheimer's disease by enhancing autophagy, a cellular process that helps maintain homeostasis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}